Given the successful trials of the noncovalent BTK inhibitor fenebrutinib in RA and the covalent BTK inhibitors tolebrutinib in MS and rilzabrutinib in ITP, it appears that that both types of BTK inhibitors have a future in autoimmune therapeutic treatment. This evidence concerns the gene BTK and rheumatoid arthritis.